|
Top Story
R&D Tax Credit: Refuting the Myths
There’s no time like the present for pharm execs to evaluate whether they’re taking full advantage of the R&D tax credit. President Obama signed into law a bill that retroactively extends it for expenses paid or incurred in 2014. But many companies aren’t claiming these credits because of common misconceptions. Here, Chai Hoang and Chris Bard dispel the myths ...Read more
Regulatory
More Guidance, Fewer Warnings on Advertising
FDA officials have been busy rolling out advisories for pharma marketers, and there’s no let-up in sight. The OPDP’s Tom Abrams recently reported that his office issued five draft guidances in the past 12 months, two dealing with social media, and the most recent making changes to drug labeling information in consumer print advertising. Jill Wechsler reports ...Read more
Marketing & Communications
Pharma’s Love Affair with Buzzwords
The commercial side of the pharma business has an unhealthy obsession with “buzzwords,” writes Lundbeck’s Timonthy White. From Value Added “Beyond the Pill” Patient-Centric Services to Integrated Multichannel Customer Centric Closed Loop Marketing, it often seems companies spend more time marketing their own innovative ideas than actually innovating for patients, caregivers, and healthcare professionals ...Read more
Leadership
Pharm Exec’s 2015 Emerging Pharma Leaders — Nominate Now!
Pharm Exec is looking for the fresh faces of pharma leadership, and we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague — or yourself. The deadline for this year’s entries is April 15
...Read more
Europe
Precision Medicine or Personalized Medicine? What’s in a Name?
President Obama's announcement in his January State of the Union address of an initiative in precision medicine has set Europe a-flutter over its use of the term 'personalized medicine'. Peter O'Donnell reports ...Read more
|
